Clinical Insights
Pediatric Adrenal Insufficiency: Etiology, Diagnosis, and Management
Mitchell Geffner, MD, Co-Director, Congenital Adrenal Hyperplasia Clinic, and Ron Burkle Chair, Center for Endocrinology, Diabetes, and Metabolism, Children’s Hospital of Los Angeles, discusses the etiology, diagnosis, and management of pediatric adrenocortical...
Efgartigimod in Juvenile Generalized Myasthenia Gravis
Abigail Schwaede, MD, Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses results on intravenous efgartigimod in juvenile generalized myasthenia gravis (gMG).
Maternal and Neonatal Outcomes of Chenodeoxycholic Acid Treatment in Pregnant Women With Cerebrotendinous Xanthomatosis
A study published in the Journal of Clinical Lipidology evaluated maternal and neonatal outcomes of chenodeoxycholic acid (CDCA) treatment during gestation in women with cerebrotendinous xanthomatosis (CTX).
Prospective Cutaneous Lymphoma International Prognostic Index Study
Julia Scarisbrick, MD, discusses the the PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) study and challenges in the diagnosis of cutaneous T-cell lymphoma (CTCL).
More
Maralixbat’s Effect on Xanthoma Severity in Children With Alagille Syndrome
A study published in The Journal of Pediatrics describes a post hoc analysis of clinical trials evaluating maralixibat in children with Alagille syndrome and its effect on xanthoma severity....
Growth Hormone Deficiency: Causes, Early Detection, and Treatment
Robert Rapaport, MD, Professor of Pediatric Endocrinology, and Director of the Comprehensive Growth Center at the Icahn School of Medicine, Mount Sinai Medical Center, New York City, discusses the...
FDA Approves Cavhanza (Nilotinib) Oral Tablet Formulation for First-Line Treatment of Ph+ Chronic Myeloid Leukemia
The US Food and Drug Administration (FDA) has approved Cavhanza (nilotinib) orally disintegrating tablets for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)....
Results from the ADAPT SERON Clinical Trial of Efgartigimod IV in Patients With Seronegative Generalized Myasthenia Gravis
James Howard Jr., MD, Professor of Neurology at the University of North Carolina at Chapel Hill, discusses results from the ADAPT SERON clinical trial of efgartigimod IV in patients with...
METEOROID Clinical Trial of Enspryng (Satralizumab) in Patients With MOGAD
Michael Levy, MD, PhD, Neuroimmunologist and Associate Professor at Harvard Medical School, discusses results from the METEOROID clinical trial of Enspryng (satralizumab) in patients with myelin...
FDA Approves Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
The US Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare, aggressive CD4+ CD56+ myeloid...
New Trial to Compare Rituximab With Targeted Therapies in Patients With Neuromyelitis Optica Spectrum Disorder
Sumaira Ahmed, Founder and Executive Director of The Sumaira Foundation, discusses her organization and the BEST-NMOSD clinical trial for patients with neuromyelitis optica spectrum disorder...
Arginine Vasopressin Deficiency (AVP-D) Overview
Christopher Romero, MD, a pediatric endocrinologist at Mount Sinai Medical Center, New York City, and Associate Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai discusses...
June Is CAH Awareness Month
June is CAH Awareness Month, a time dedicated to increasing understanding of congenital adrenal hyperplasia (CAH) and supporting the individuals and families impacted by this rare genetic condition....
DUET Clinical Trial of Xywav in Patients With Narcolepsy
Logan Schneider, MD, Adjunct Clinical Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, discusses the DUET clinical trial of Xywav (low sodium oxybate) in patients...
Data Presented on Myasthenia Gravis at the 2026 American Academy of Neurology Meeting
Omar Sinno, MD, US Medical Strategy Lead for Rare Disease at UCB Pharma, discusses data presented on myasthenia gravis (MG) at the 2026 American Academy of Neurology meeting. MG is a...
Itvisma Gene Therapy for Patients With Spinal Muscular Atrophy
John Day, MD, PhD, Director of Neuromuscular Medicine at Stanford University, discusses the development of Itvisma gene therapy for patients with spinal muscular atrophy (SMA). SMA is...
Upcoming Regulatory Decision for LNTH-2501 in the Imaging of Neuroendocrine Tumors
Mauro Cives, MD, Associate Professor of Medical Oncology at the University of Bari, Italy, discusses the upcoming regulatory decision for LNTH-2501 to improve imaging of neuroendocrine tumors...
Results From the ACUITY Clinical Trial in Patients With Acute Optic Neuritis
Pablo Villoslada, MD, PhD, Founder and Medical Director of Accure Therapeutics and Head of Pathogenesis and New Therapies MS at IDIBAPS in Hospital Clínic in Barcelona, discusses results from the...
Outcomes of Pegcetacoplan Treatment in Adolescents With C3G and IC-MPGN
A recent publication in the Clinical Journal of the American Society of Nephrology presented outcomes of pegcetacoplan treatment in adolescents with C3 glomerulopathy (C3G) and primary immune...
Oxbryta (Voxelotor) Clinical Study Analysis Strives to Get Sickle Cell Disease Treatment Back on Market
A recent clinical study analysis of Oxbryta (voxelotor), globally withdrawn in 2024, was submitted to the FDA with the intent of getting voxelotor back on the market. Sickle cell disease (SCD) is a...
Efficacy of Efgartigimod To Treat Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): ADHERE Trial
Hans Katzberg, MD, Professor of Neurology at the University of Toronto and Neurologist at Toronto General Hospital, discusses post hoc analyses from the ADHERE clinical trial in chronic inflammatory...
Key Features of PLGD-1
Angela Zhu, MD, is an Ophthalmologist and Clinical Assistant Professor, Pediatric & Adult Cornea/Cataract/External Diseases, at Bascom Palmer Eye Institute in Miami. In this interview with...
Primary Analysis of KYV-101 for the Treatment of Stiff Person Syndrome
Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses primary analysis of KYV-101 for the treatment of stiff person syndrome (SPS). SPS is a...
Narcolepsy Breakthroughs and Emerging Therapies
Emmanuel Mignot, MD, PhD, is one of the pioneers in the study of narcolepsy and served a vital role in discerning the genetic cause of this rare and underdiagnosed disorder. Dr. Mignot, Professor of...
Recent Videos
Social Wall
John Day, MD, PhD, Director of Neuromuscular Medicine at Stanford University, discusses the development of Itvisma gene therapy for patients with spinal muscular atrophy (SMA).
https://checkrare.com/itvisma-gene-therapy-for-patients-with-spinal-muscular-atrophy/
#CheckRare ...#RareMusculoskeletal #RareNeurology #SMA #SpinalMuscularAtrophy #DrugDevelopment
CheckRare is excited to once again serve as a media partner for the World Orphan Drug Congress.
This event brings together leaders, innovators, advocates, and experts from across the rare disease community to share insights, discuss emerging trends, and explore opportunities to
James Howard Jr., MD, Professor of Neurology at the University of North Carolina at Chapel Hill, discusses results from the ADAPT SERON clinical trial of efgartigimod IV in patients with seronegative generalized myasthenia gravis (gMG). Data from this trial was pivotal in
The Future of Pediatric Adrenal Insufficiency
Addressing Stress Triggers in Pediatric Adrenal Insufficiency
Cortisol Replacement Therapy for Pediatric Adrenal Insufficiency
Signs and Symptoms of Pediatric Adrenal Insufficiency
Pediatric Adrenal Insufficiency Diagnostic Delays
Pediatric Adrenal Insufficiency Overview
Pediatric Adrenal Insufficiency: Etiology, Diagnosis, and Management
Treatment Advances in Growth Hormone Deficiency
James Howard Jr., MD, Professor of Neurology at the University of North Carolina at Chapel Hill, discusses results from the ADAPT SERON clinical trial of efgartigimod IV in patients with seronegative generalized myasthenia gravis (gMG). Data from this trial was pivotal in efgartigimod’s recent ...FDA approval.
Learn more at https://checkrare.com/results-from-the-adapt-seron-clinical-trial-of-efgartigimod-iv-in-patients-with-seronegative-generalized-myasthenia-gravis/
#CheckRare #MyastheniaGravis #RareNeurology #RareAutoimmune #RareMusculoskeletal #ClinicalTrial #DrugDevelopment
Even though the ligneous lesions on the eye are generally the first symptom of PLGD-1, the deficiency can present in many different ways (and in virtually any organ system with mucous membranes).
Learn about the key features of disease at ...https://checkrare.com/diagnosis-and-management-of-plasminogen-deficiency-2/
#CheckRare
Even though the ligneous lesions on the eye are generally the first symptom of PLGD-1, the deficiency can present in many different ways (and in virtually any organ system with mucous membranes).
Learn about the key features of disease at ...https://checkrare.com/diagnosis-and-management-of-plasminogen-deficiency-2/
#CheckRare #PLGD #RareGenetic #RareDisease
Impact of Vyvgart (Efgartigimod Alfa) Approval for Patients with Seronegative Myasthenia Gravis












The Future of Pediatric Adrenal Insufficiency
CheckRare June 10, 2026 11:18 am